Raymond James & Associates’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Raymond James & Associates’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21,500	Closed	-$12K	–	3827
2019 Q3	$12K	Buy	+21,500	New	+$12K	﹤0.01%	3558

Raymond James & Associates's CELGZ Position: Q4 2019 in Review

Raymond James & Associates sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 21,500 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in CELGZ in Q3 2019 and held it in 1 quarter. The position peaked at $12K in Q3 2019. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.

Raymond James & Associates reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
Raymond James & Associates sold 21,500 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $12K.
Raymond James & Associates first reported a position in Celgene Corporation Contingent Value Rights in Q3 2019 and held it in 1 quarter.
Raymond James & Associates's Celgene Corporation Contingent Value Rights position peaked at $12K in Q3 2019.
0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.

Based on Raymond James & Associates's 13F filing for Q4 2019, filed 12 Feb 2020.